FDA Expands ANKTIVA® Approval for BCG — Unresponsive Non — Muscle — Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
For best results when printing this announcement, please click on link below: FDA Expands ANKTIVA(® )Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease Expanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer